Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGunsynd Regulatory News (GUN)

Share Price Information for Gunsynd (GUN)

Share Price is delayed by 15 minutes
Get Live Data
0.11    0.0025 (2.33%)
Bid:
0.10
Ask:
0.12
Spread: 0.02 (20.00%)
Market Cap: £1.62m
GUN Live PriceLast checked at - London Stock Exchange

Intraday Gunsynd Share Chart

Additional Investment - Eagle Mountain Mining

14 Oct 2020 12:11

RNS Number : 0877C
Gunsynd PLC
14 October 2020
 

Gunsynd plc

 

("Gunsynd" or the "Company")

 

Additional Investment - Eagle Mountain Mining

 

Gunsynd Plc (AIM: GUN, AQSE: GUN) is pleased to announce that further to the announcement made on 21 September 2020, it has invested an additional A$125,000 (approximately £70,000) in Eagle Mountain Mining Limited ("Eagle Mountain"), an ASX listed copper-gold exploration and development company (ASX: EM2).

 

The Eagle Mountain investment was executed on the following terms:

· subscription for 416,667 ordinary shares at A$0.30c for a total consideration of A$125,000;

· the investment is a part of a of A$1.5 million capital raising supported by institutional investors;

· Silver Mountain Nominee Pty Ltd, an entity associated with Eagle Mountain's Managing Director, Charles Bass, exercised 4.5 million options in Eagle Mountain, contributing A$1.35 million;

· the funds will be used by Eagle Mountain to primarily extend the drilling program at the high-grade Oracle Ridge Copper Mine in Arizona and continue near mine exploration; and

· Gunsynd PLC now holds 2,563,172 shares in Eagle Mountain representing approximately 1.8% of its issued share capital.

 

About Eagle Mountain Mining Limited

Eagle Mountain Mining Limited (ASX: EM2), established in 2017, is a copper-gold explorer focused on the strategic exploration and development of advanced and greenfield projects in Arizona.

 

Arizona is at the heart of America's mining industry and home to some of the world's largest copper discoveries, now owned by major mining companies including BHP, Rio Tinto, Freeport McMoRan and Hudbay. Eagle Mountain's Oracle Ridge and Silver Mountain Projects are within the Laramide Arc which hosts many of these significant copper porphyry deposits.

 

Oracle Ridge is a high grade, advanced stage underground copper/gold/silver project. The project includes an NI43-101 resource of 11.7mt at 1.57%Cu, 17.47g/t Ag and 0.18g/t Au. Eagle Mountain believes there is significant potential to expand the known resources through additional drilling, along with exploration at depth to define the source of the mineralisation.

 

Peter Ruse, a director of Gunsynd, commented: "Gunsynd was pleased to have opportunity to participate in the latest financing in Eagle Mountain. The company's drilling program is well progressed, and this additional capital allows the company to continue the drilling program on an expanded basis. The options exercise by the Founder and CEO - Charles Bass demonstrates a strong signal of support and is encouraging for all shareholders. We look forward to results from the drilling program in due course."

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the Company's ability to execute and implement future plans, and the occurrence of unexpected events. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors.

The Directors of Gunsynd accept responsibility for this announcement.

 

 

For further information please contact:

 

Gunsynd plc

Hamish Harris/ Peter Ruse

 

 

+44 (0) 78 7958 4153

Cairn Financial Advisers LLP

James Caithie / Liam Murray

 

+44 (0) 20 7213 0880

 

Peterhouse Capital Limited

Lucy Williams

 

+44 (0) 20 7469 0936

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURGZMMGMDRGGZM
Date   Source Headline
8th Jul 20117:00 amRNSChange of Registered Office
21st Jun 201111:00 amRNSDirectorate Change
23rd May 201111:45 amRNSResult of General Meeting
11th May 201111:17 amRNSDirector's Dealing
6th May 20117:00 amRNSAcquisition and Placing to raise £2 million
27th Apr 20112:30 pmRNSBusiness Update
8th Mar 20117:00 amRNSInterim Results
2nd Mar 20113:12 pmRNSHolding(s) in Company
25th Feb 20117:00 amRNSHolding(s) in Company
20th Jan 20111:23 pmRNSResult of AGM
17th Jan 20117:00 amRNSSyntopix to research biofilms for Beiersdorf AG
14th Jan 201110:13 amRNSPosting of Annual Report and notice of AGM
3rd Dec 20107:00 amRNSGrant of share options to Directors
29th Nov 20107:00 amRNSFinal Results
11th Nov 20107:00 amRNSAppointment of Broker
1st Nov 20107:00 amRNSSecond Agreement with Sinclair Pharma
29th Sep 20105:05 pmRNSHolding(s) in Company
27th Sep 20102:51 pmRNSHolding(s) in Company
23rd Aug 20107:00 amRNSAgreement with Global Consumer Products Company
22nd Jun 20103:20 pmRNSDirectorate Change
22nd Apr 20107:00 amRNSAgreement with Sinclair Pharma plc
31st Mar 201011:25 amRNSResult of General Meeting
15th Mar 201011:08 amRNSProposed Fundraising
12th Mar 20107:00 amRNSInterim Results
3rd Feb 20107:00 amRNSDirectorate Change
2nd Feb 20102:30 pmRNSResult of AGM
7th Jan 20107:00 amRNSPreliminary results
12th Nov 20097:00 amRNSBusiness Update
12th Nov 20097:00 amRNSClinical results from Phase II cosmetic study
28th Apr 20097:00 amRNSHalf Yearly Report
14th Apr 20097:00 amRNSRe Contract
3rd Nov 20087:00 amRNSFinal Results
25th Sep 20087:00 amRNSChange of Adviser
29th Aug 20087:00 amRNSTotal Voting Rights
12th Aug 200811:58 amRNSHolding(s) in Company
6th Aug 20081:13 pmRNSResult of EGM & Director's In
15th Jul 20087:00 amRNSProposed fundraising
3rd Jul 20087:00 amRNSProctor & Gamble Agreement
24th Apr 20087:00 amRNSInterim Results
25th Feb 20087:00 amRNSPositive Trial Results
4th Feb 200810:51 amRNSHolding(s) in Company
21st Dec 20072:50 pmRNSOral Healthcare Agreement
15th Nov 20074:03 pmRNSAnnual Report and Accounts
18th Oct 20077:01 amRNSPreliminary Results
16th Aug 20077:00 amRNSPhase I Results
13th Jun 20077:01 amRNSPhase I Acne Trial Starts
8th May 20077:02 amRNSCRO Appointment
30th Apr 20079:00 amRNSTotal Voting Rights
25th Apr 200710:45 amRNSDirector/PDMR Shareholding
24th Apr 20074:12 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.